Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
0.7090
-0.0370 (-4.96%)
Mar 31, 2025, 2:20 PM EDT - Market open
Xilio Therapeutics Analyst Ratings
Total Analysts
1
Consensus Rating
Buy
Price Target
$4.00
Upside
+464.20%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Raymond James | Raymond James | Buy Maintains $6 → $4 | Buy | Maintains | $6 → $4 | +464.20% | Nov 8, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +887.35% | May 30, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +887.35% | May 11, 2023 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $20 → $10 | Buy | Maintains | $20 → $10 | +1,310.50% | Jan 27, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +887.35% | Dec 21, 2022 |
| Raymond James | Raymond James | Buy Maintains $31 → $13 | Buy | Maintains | $31 → $13 | +1,733.65% | Nov 10, 2022 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $32 → $20 | Buy | Maintains | $32 → $20 | +2,720.99% | Aug 10, 2022 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $36 | Strong Buy | Initiates | $36 | +4,977.79% | Jan 10, 2022 |
| Raymond James | Raymond James | Buy Initiates $31 | Buy | Initiates | $31 | +4,272.54% | Nov 16, 2021 |
| Cowen & Co. | Cowen & Co. | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Nov 16, 2021 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $32 | Buy | Initiates | $32 | +4,413.59% | Nov 16, 2021 |